Genentech has revealed negative results from the IMblaze370 study, a Phase III trial investigating Tecentriq (atezolizumab) in combination with Cotellic (cobimetinib) to treat patients with heavily pre-treated, locally advanced or metastatic colorectal cancer (CRC).

The multi-centre, open-label, three-arm, randomised trial enrolled 363 people with difficult-to-treat locally advanced or metastatic colorectal cancer who have received at least two prior regimens of chemotherapy for metastatic disease.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

It also compared a standard of care therapy regorafenib with Cotellicplus Tecentriq and Tecentriq monotherapy.

During the trial, patients were randomised at 2:1:1 ratio to receive Tecentriq plus Cotellic, or Tecentriq, or Regorafenib.

Patients in the combination arm received Cotellicon days one to 21 plus Tecentriq on day one and day 15 in a 28-day cycle.

Participants in the monotherapy arm received Tecentriq on day one of each 21-day cycle, while those in the control arm received regorafenib on days one to 21 in a 28-day cycle, until loss of clinical benefit.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“We have a number of studies evaluating medicines in colorectal cancer that could play an important role in the treatment of people with this disease in the future.”

The trial’s primary endpoint was overall survival, while key secondary endpoints comprised progression-free survival (PFS), overall response rate (ORR) and duration of response (DoR).

The trial was unable to meet its primary endpoint of overall survival (OS) compared to regorafenib.

Genentech chief medical officer and global product development head Sandra Horning said: “While these results are not what we hoped for, we remain committed to applying our deep experience to develop medicines that will improve outcomes for people living with gastrointestinal cancers.

“In particular, we have a number of studies evaluating medicines in colorectal cancer that could play an important role in the treatment of people with this disease in the future.”

Genentech expects to further evaluate the results from IMblaze370 and present them at an upcoming medical meeting.